{Reference Type}: Journal Article
{Title}: A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma.
{Author}: Goodman CD;DeMonte F;Nguyen TP;Garden AS;Wang CH;Wang XA;Diao K;Lee A;Reddy J;Moreno A;Spiotto M;Fuller CD;Rosenthal D;Ferrarotto R;Raza SM;Su SY;Warner A;Hanna E;Phan J;
{Journal}: Head Neck
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 29
{Factor}: 3.821
{DOI}: 10.1002/hed.27887
{Abstract}: <B>BACKGROUND: </B>Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.<BR><B>METHODS: </B>ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.<BR><B>RESULTS: </B>Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.<BR><B>CONCLUSIONS: </B>In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.